Steven Johnson has been appointed chief development officer at Zealand Pharma A/S as the Danish company embarks on a collaboration with the Roche Group to co-develop a therapy for obesity. Mr Johnson most recently led late-stage clinical development and global regulatory affairs at UCB Biopharma. Previously he held senior positions as MedPace Inc, a contract research organisation, and at Novo Nordisk A/S. He began his career as a reviewer at the US Food and Drug Administration in the division of metabolic and endocrine drug products.
Zealand Pharma announced the appointment on 19 May 2025.
Copyright 2025 Evernow Publishing Ltd